CN104436160A - Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry - Google Patents
Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry Download PDFInfo
- Publication number
- CN104436160A CN104436160A CN201410623503.4A CN201410623503A CN104436160A CN 104436160 A CN104436160 A CN 104436160A CN 201410623503 A CN201410623503 A CN 201410623503A CN 104436160 A CN104436160 A CN 104436160A
- Authority
- CN
- China
- Prior art keywords
- colistin
- compound medicine
- blumea herb
- balsamiferou blumea
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compositae blumea plant, namely balsamiferou blumea herb, and colistin containing compound medicine for livestock and poultry. The compound medicine is prepared from the following raw materials in parts by weight: 3-30 parts of colistin and 5-200 parts of balsamiferou blumea herb. According to the compound medicine, after the balsamiferou blumea herb is added into the colistin, the colistin resistance of bacteria can be reversed, so that the treatment effect of the colistin is improved. By preparing the compound medicine into powder, tablets, oral liquids or granules according to the conventional methods, and feeding in a manner of adding the powder, tablets, oral liquids or granules into livestock and poultry feed according to the ratio of (0.1-7)g: 1kg, the medication cost and drug residue can be greatly reduced, higher economic benefits are created for farmers, and meanwhile, food safety is ensured.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, particularly relate to a kind of poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and colistin.
Background technology
Escherichia coli are common conditioned pathogens, also be the normal a kind of disease sent out, it can formerly have been carried out the coffin upon burial the multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis, also can secondary or mixedly to send out in virosis, causes huge economic loss to aquaculture.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, and the report about Drug Resistance of E. coli is also more.Research confirms, one of main mechanism of drug resistance produces beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be hydrolyzed beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it not only to cephalo three generations and aztreonam drug resistance, and is crossing drug resistant to aminoglycoside, quinolones and sulfonamides, only to carbapenems, a mould alkene class medicaments insensitive.Many documents reported colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to comparatively pay close attention to.Inventor has carried out the detection of food animal source pathogenic bacterium ESBLs recently, extraction, enzyme press down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; show the colibacillary drug sensitive test of part ESBLs, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in serious multidrug resistant.Inventor is separated to the escherichia coli of resistance to fosfomycin product fosA3 drug resistant gene producing in ESBLs bacterial strain, more strengthen the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and brings larger economic loss, and increase poultry drug residue risk to production.Therefore, the escherichia coli needing a kind of drug resistance to no matter whether in actual production badly can have the medicine of better therapeutical effect, and can shorten treatment course for the treatment of, reduce mortality rate, reduce economic loss and reduce drug residue, for raiser creates higher economic benefit, also ensureing that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and colistin, it can kill antibacterial quickly, overcome large, the residual high and defect that cost is high of weak curative effect that antimicrobial drug treatment causes due to drug resistance problems, consumption, avoid that simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and colistin, is made up of the raw material of following weight portion: colistin 3-30 part, Balsamiferou Blumea Herb 5-200 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Balsamiferou Blumea Herb was pulverized 60 mesh sieves, then mixes with pulverous antimicrobial drug, is prepared into powder, tablet, oral liquid or granule according to a conventional method.
For the drug resistance problems that current poultry coli-infection exists, inventor utilizes Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and antimicrobial drug to form compound medicine.Research proves, after adding Balsamiferou Blumea Herb in antimicrobial drug, can reverse bacterial to the drug resistance of antimicrobial drug, thus improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule, add in animal and fowl fodder according to the 0.1-7g principal agent/addition of kg feedstuff and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also ensure that food safety simultaneously.
Detailed description of the invention
One, Balsamiferou Blumea Herb is to the drug resistance inversion Effect study of antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but has stronger drug resistance due to the escherichia coli producing ESBLs drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Balsamiferou Blumea Herb to antimicrobial drug, 96 orifice plates adopt microtest tube doubling dilution, first determine antimicrobial drug to producing the minimal inhibitory concentration of e. coli strains of ESBLs and fosA3 drug resistant gene and Balsamiferou Blumea Herb to the subinhibitory concentration producing ESBLs and fosA3 drug resistant gene e. coli strains, the Balsamiferou Blumea Herb then adding subinhibitory concentration in the medium reuses microtest tube doubling dilution and cultivates the minimal inhibitory concentration measuring antimicrobial drug; Continuous passage method is utilized to carry out Secondary Culture to product ESBLs and fosA3 drug resistant gene e. coli strains in the culture medium being added with same subinhibitory concentration Balsamiferou Blumea Herb and same concentration antimicrobial drug, until the antimicrobial drug minimal inhibitory concentration observed diminishes more than 4 times compared with before going down to posterity, can be judged as that Balsamiferou Blumea Herb has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) Balsamiferou Blumea Herb goes down to posterity and causes the change (μ g/mL) of product ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of antibiotic-resistance E. coli, can judge that Balsamiferou Blumea Herb has drug resistance inversion effect to product ESBLs and fosA3 drug resistant gene escherichia coli.
Two, the application example of compound medicine of the present invention
Embodiment 1-embodiment 6 is prepared: after Balsamiferou Blumea Herb being pulverized 60 mesh sieves according to table 2 formula and following methods, based on raw material, again with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine is prepared into formulation products.
The formula of table 2 embodiment 1-6 and preparation dosage form
| Numbering | Antimicrobial drug | Balsamiferou Blumea Herb | Dosage form |
| Embodiment 1 | Colistin 10g | 170g | Powder |
| Embodiment 2 | Colistin 3g | 60g | Tablet |
| Embodiment 3 | Colistin 18g | 15g | Oral liquid |
| Embodiment 4 | Colistin 30g | 120g | Granule |
| Embodiment 5 | Colistin 3g | 5g | Powder |
| Embodiment 6 | Colistin 30g | 200g | Tablet |
Inventor, by the compound medicine product of above-described embodiment 1-6 gained, on Guangxi Qinzhou pig farm, carries out efficacy experiment to the piglet diarrhea of 33 ages in days.
Clinical symptoms: this swinery, after wean is turn-taked, starts to occur diarrhoea, draws watery stools, feces contains indigested feedstuff, pig material feeding but be exactly not long, and diarrhea of pigs dehydration serious is individually dead, do not occur symptoms of emesis, raiser uses multi-medicament, and treatment does not all occur ideal effect.
Cut open inspection pathological changes: after cuing open inspection, Intestinum Sus domestica wall is belittled, especially small intestinal rear end and colon site, and intestinal mucosa comes off, and intestinal wall is congested, hemorrhage.
Laboratory diagnosis: get pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivated by escherichia coli, biochemical test is differentiated, judges that Infection in Piglets is bacillus coli, pcr amplification, proves to produce the ESBLs drug resistant gene and the fosA3 drug resistant gene that there are CTX-M type.
Test therapeutic regimen: morbidity swinery divides 8 groups of administrations, first group with the addition administration of embodiment 1 according to 1.8g/kg feedstuff, second group with the addition administration of embodiment 2 according to 2g/kg feedstuff, 3rd group with the addition administration of embodiment 3 according to 0.2g/kg feedstuff, the 4th group with the addition administration of embodiment 4 according to 0.4g/kg feedstuff; 5th group with the addition administration of embodiment 5 according to 0.25g/kg feedstuff, the 6th group with the addition administration of embodiment 6 according to 0.75g/kg feedstuff; 7th group with the addition administration of colistin powder according to 0.1g/kg feedstuff, the 8th group with the addition administration of the thick powder of Balsamiferou Blumea Herb according to 4g/kg feedstuff; Above eight groups of therapeutic regimens all continue use 5 days.
Result of use is fed back: first group to the 6th group medication is after 2 days, and swinery no longer draws watery stools, formed stools, and no longer containing feedstuff in feces, continue use 3 days, swinery is fully recovered; 7th group of medication is after 2 days, and swinery is still unhealthy, continues use 3 days, substantially get well, but still draw pasty state feces individually, but drug withdrawal is after 3 days, and recurrence appears in swinery; 8th group of medication is after 2 days, and swinery is without remarkable improvement, and continue use 3 days, swinery continues to have loose bowels, and all the other are also more serious individually.Visible, the compound medicine containing Balsamiferou Blumea Herb is better than folk prescription to swinery curative effect.
Claims (2)
1. contain a poultry compound medicine for Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and colistin, it is characterized in that, be made up of the raw material of following weight portion: colistin 3-30 part, Balsamiferou Blumea Herb 5-200 part.
2. the poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and colistin according to claim 1, it is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410623503.4A CN104436160A (en) | 2014-11-07 | 2014-11-07 | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410623503.4A CN104436160A (en) | 2014-11-07 | 2014-11-07 | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104436160A true CN104436160A (en) | 2015-03-25 |
Family
ID=52883419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410623503.4A Pending CN104436160A (en) | 2014-11-07 | 2014-11-07 | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104436160A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177904A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and colistin |
| CN106267154A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and colistin |
| CN106267153A (en) * | 2016-08-22 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and colistin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073623A (en) * | 2012-12-28 | 2013-05-01 | 三达膜科技（厦门）有限公司 | Separation and purification method for colistin sulfate |
| CN103907792A (en) * | 2014-04-27 | 2014-07-09 | 周宇晨 | Composite pig feed for enhancing immunity and promoting growth |
| CN103933544A (en) * | 2014-04-25 | 2014-07-23 | 广西大学 | Creat/colimycin-containing compound medicine for livestock and fowl |
| CN103933109A (en) * | 2014-04-15 | 2014-07-23 | 广西大学 | Method for treating animal escherichia coli infected diseases |
-
2014
- 2014-11-07 CN CN201410623503.4A patent/CN104436160A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073623A (en) * | 2012-12-28 | 2013-05-01 | 三达膜科技（厦门）有限公司 | Separation and purification method for colistin sulfate |
| CN103933109A (en) * | 2014-04-15 | 2014-07-23 | 广西大学 | Method for treating animal escherichia coli infected diseases |
| CN103933544A (en) * | 2014-04-25 | 2014-07-23 | 广西大学 | Creat/colimycin-containing compound medicine for livestock and fowl |
| CN103907792A (en) * | 2014-04-27 | 2014-07-09 | 周宇晨 | Composite pig feed for enhancing immunity and promoting growth |
Non-Patent Citations (1)
| Title |
|---|
| 刘国道著: "《海南饲料及兽医中草药植物》", 30 September 2006, article "菊科：艾纳香" * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177904A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and colistin |
| CN106267153A (en) * | 2016-08-22 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and colistin |
| CN106267154A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and colistin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103127508B (en) | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103961400A (en) | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry | |
| CN103948656A (en) | Creat/fosfomycin-containing compound medicine for livestock and fowl | |
| CN103977088A (en) | Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry | |
| CN103301463A (en) | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN104027369A (en) | Plumbago zeylanica and norfloxacin containing compound composition for livestock and poultry | |
| CN103961401A (en) | Compound medicine comprising herba lycopi and sulfamonomethoxine sodium and used for livestock and poultry | |
| CN103948677A (en) | Boneset/amoxicillin-containing compound medicine for livestock and fowl | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN103948912B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and colistin | |
| CN104436161A (en) | Pteris multifida and colistin-containing compound drug for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry | |
| CN104027370A (en) | Plumbago zeylanica and mequindox containing compound composition for livestock and poultry | |
| CN104435013A (en) | Pteris multifida and amikacin-containing compound drug for livestock and poultry | |
| CN104840502A (en) | Composition containing epimedium herb and mequindox and used for livestock and poultry, and preparation method thereof | |
| CN103933085B (en) | The application of Herba Andrographitis and phosphonomycin in the compound medicine for preparing treatment livestock and poultry coli-infection disease | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN104162145A (en) | Acalypha australis L. and colistin-containing compound medicine for livestock and poultry | |
| CN104840942A (en) | Composition containing epimedium herb and colistin and used for livestock and poultry, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |
|
| RJ01 | Rejection of invention patent application after publication |